Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ceres Power slashes full-year sales guidance

(Sharecast News) - Clean energy group Ceres Power has scaled back its full-year sales guidance by nearly 40% after reporting weaker results for the first half. The company, whose business focuses on licensing fuel cell and electrolyser technology, said on Friday that the "most probable revenue outturn" for 2025 will now be just £32m due to the uncertain timing of a new manufacturing licence agreement.

Current forecasts are for a figure closer to £52.5m, according to company-compiled consensus estimates, after Ceres guided to a "broadly similar" top line to 2024 at the time of its annual results in March.

"The company is in later stage negotiation regarding a new manufacturing licence agreement but recognises that completion and timing of revenue recognition are uncertain. If successful, any revenue recognised in the current year would be in addition to the above guidance," the firm said.

The news came alongside Ceres's interim results, which showed that revenues fell 26% year-on-year to £21.1m, which it attributed to strong comparatives following a significant one-off licence with partner Delta in 2024.

Along with a fall in the gross margin to 79% from 80%, the adjusted EBITDA loss increased to £11.3m from £9.0m a year earlier.

Chief executive Phil Caldwell expressed the need to adapt to "changing market opportunities" and said the company was kicking off a business transformation programme to drive the next phase of growth.

"We are seeing an unprecedented change in the market with an acute need for power to service the demand of AI-data centres and increased electrification of society which represents a major market opportunity for the business. The emergence of this market has coincided with Doosan's start of mass manufacture of Ceres-based products and marks a key inflection point as we transition from being an R&D-led organisation to a commercially focused business," he said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.